{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T11:47:02Z","timestamp":1782301622910,"version":"3.54.5"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.ejmech.2014.05.076","type":"journal-article","created":{"date-parts":[[2014,6,2]],"date-time":"2014-06-02T20:16:13Z","timestamp":1401740173000},"page":"521-535","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Development of second generation EP2 antagonists with high selectivity"],"prefix":"10.1016","volume":"82","author":[{"given":"Thota","family":"Ganesh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxiong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ray","family":"Dingledine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2014.05.076_bib1","doi-asserted-by":"crossref","DOI":"10.1021\/jm401431x","article-title":"Prostanoid receptor EP2 as a therapeutic target","author":"Ganesh","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2014.05.076_bib2","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.tips.2013.05.003","article-title":"Prostaglandin receptor EP2 in the crosshairs of anti-inflammation, anti-cancer, and neuroprotection","volume":"34","author":"Jiang","year":"2013","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2014.05.076_bib3","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1523\/JNEUROSCI.4485-03.2004","article-title":"Neuroprotective function of the PGE2 EP2 receptor in cerebral ischemia","volume":"24","author":"McCullough","year":"2004","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ejmech.2014.05.076_bib4","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.exer.2011.02.015","article-title":"Effect of PF-04217329 a prodrug of a selective prostaglandin EP(2) agonist on intraocular pressure in preclinical models of glaucoma","volume":"93","author":"Prasanna","year":"2011","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.ejmech.2014.05.076_bib5","doi-asserted-by":"crossref","first-page":"809","DOI":"10.3109\/02713683.2011.593725","article-title":"A\u00a0phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension","volume":"36","author":"Schachar","year":"2011","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.ejmech.2014.05.076_bib6","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/ICO.0b013e3182523f40","article-title":"Subclinical increased anterior stromal reflectivity with topical taprenepag isopropyl","volume":"32","author":"Schachar","year":"2013","journal-title":"Cornea"},{"key":"10.1016\/j.ejmech.2014.05.076_bib7","doi-asserted-by":"crossref","first-page":"10180","DOI":"10.1523\/JNEUROSCI.3591-05.2005","article-title":"Deletion of the prostaglandin E2 EP2 receptor reduces oxidative damage and amyloid burden in a model of Alzheimer's disease","volume":"25","author":"Liang","year":"2005","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ejmech.2014.05.076_bib8","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1742-2094-4-2","article-title":"Prostaglandin E2 receptor subtype 2 (EP2) regulates microglial activation and associated neurotoxicity induced by aggregated alpha-synuclein","volume":"4","author":"Jin","year":"2007","journal-title":"J.\u00a0Neuroinflammation"},{"key":"10.1016\/j.ejmech.2014.05.076_bib9","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ana.21437","article-title":"The prostaglandin E2 EP2 receptor accelerates disease progression and inflammation in a model of amyotrophic lateral sclerosis","volume":"64","author":"Liang","year":"2008","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ejmech.2014.05.076_bib10","doi-asserted-by":"crossref","first-page":"14850","DOI":"10.1523\/JNEUROSCI.3922-11.2011","article-title":"Ablation of cyclooxygenase-2 in forebrain neurons is neuroprotective and dampens brain inflammation after status epilepticus","volume":"31","author":"Serrano","year":"2011","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ejmech.2014.05.076_bib11","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1084\/jem.20051310","article-title":"Prostacyclin-IP signaling and prostaglandin E2-EP2\/EP4 signaling both mediate joint inflammation in mouse collagen-induced arthritis","volume":"203","author":"Honda","year":"2006","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ejmech.2014.05.076_bib12","doi-asserted-by":"crossref","first-page":"8138","DOI":"10.4049\/jimmunol.178.12.8138","article-title":"The proinflammatory effect of prostaglandin E2 in experimental inflammatory bowel disease is mediated through the IL-23-->IL-17 axis","volume":"178","author":"Sheibanie","year":"2007","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ejmech.2014.05.076_bib13","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1096\/fj.06-7581com","article-title":"EP2 prostanoid receptor promotes squamous cell carcinoma growth through epidermal growth factor receptor transactivation and iNOS and ERK1\/2 pathways","volume":"21","author":"Donnini","year":"2007","journal-title":"FASEB J."},{"key":"10.1016\/j.ejmech.2014.05.076_bib14","doi-asserted-by":"crossref","first-page":"7019","DOI":"10.1038\/sj.onc.1209694","article-title":"EP2, a receptor for PGE2, regulates tumor angiogenesis through direct effects on endothelial cell motility and survival","volume":"25","author":"Kamiyama","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2014.05.076_bib15","doi-asserted-by":"crossref","first-page":"5507","DOI":"10.1038\/sj.onc.1209538","article-title":"Overexpression of the prostaglandin E2 receptor EP2 results in enhanced skin tumor development","volume":"25","author":"Sung","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2014.05.076_bib16","doi-asserted-by":"crossref","first-page":"10501","DOI":"10.1073\/pnas.96.18.10501","article-title":"Abortive expansion of the cumulus and impaired fertility in mice lacking the prostaglandin E receptor subtype EP(2)","volume":"96","author":"Hizaki","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2014.05.076_bib17","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/7426","article-title":"Salt-sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor","volume":"5","author":"Kennedy","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2014.05.076_bib18","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1111\/j.1476-5381.2011.01495.x","article-title":"In\u00a0vitro and in\u00a0vivo characterization of PF-04418948, a novel, potent and selective prostaglandin EP(2) receptor antagonist","volume":"164","author":"Af Forselles","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2014.05.076_bib19","doi-asserted-by":"crossref","first-page":"4173","DOI":"10.1021\/jm5000672","article-title":"Lead optimization studies of cinnamic amide EP2 antagonists","volume":"57","author":"Ganesh","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2014.05.076_bib20","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1073\/pnas.1120195109","article-title":"Small molecule antagonist reveals seizure-induced mediation of neuronal injury by prostaglandin E2 receptor subtype EP2","volume":"109","author":"Jiang","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2014.05.076_bib21","doi-asserted-by":"crossref","first-page":"9293","DOI":"10.1074\/jbc.M113.455816","article-title":"EP2 receptor signaling pathways regulate classical activation of microglia","volume":"288","author":"Quan","year":"2013","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2014.05.076_bib22","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.lfs.2003.09.031","article-title":"EP2 and EP4 prostanoid receptor signaling","volume":"74","author":"Regan","year":"2003","journal-title":"Life Sci."},{"key":"10.1016\/j.ejmech.2014.05.076_bib23","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1073\/pnas.1218498110","article-title":"Inhibition of the prostaglandin receptor EP2 following status epilepticus reduces delayed mortality and brain inflammation","volume":"110","author":"Jiang","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2014.05.076_bib24","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1021\/tx034170b","article-title":"Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development","volume":"17","author":"Evans","year":"2004","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.ejmech.2014.05.076_bib25","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/BF03226377","article-title":"Hepatic microsomal metabolism of indole to indoxyl, a precursor of indoxyl sulfate","volume":"26","author":"Banoglu","year":"2001","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.ejmech.2014.05.076_bib26","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1146\/annurev.pharmtox.41.1.661","article-title":"Prostanoid receptors: subtypes and signaling","volume":"41","author":"Breyer","year":"2001","journal-title":"Annu Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.ejmech.2014.05.076_bib27","doi-asserted-by":"crossref","first-page":"6209","DOI":"10.1021\/cr200010h","article-title":"Prostanoid receptors","volume":"111","author":"Hirata","year":"2011","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2014.05.076_bib28","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1152\/physrev.1999.79.4.1193","article-title":"Prostanoid receptors: structures, properties, and functions","volume":"79","author":"Narumiya","year":"1999","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ejmech.2014.05.076_bib29","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1126\/science.1103333","article-title":"COX-2-derived prostacyclin confers atheroprotection on female mice","volume":"306","author":"Egan","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2014.05.076_bib30","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1172\/JCI27291","article-title":"Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities","volume":"116","author":"Grosser","year":"2006","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ejmech.2014.05.076_bib31","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1021\/ac9912247","article-title":"A\u00a0high-throughput screening method for the determination of aqueous drug solubility using laser nephelometry in microtiter plates","volume":"72","author":"Bevan","year":"2000","journal-title":"Anal. Chem."},{"key":"10.1016\/j.ejmech.2014.05.076_bib32","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1124\/jpet.112.200444","article-title":"Role of prostaglandin receptor EP2 in the regulations of cancer cell proliferation, invasion, and inflammation","volume":"344","author":"Jiang","year":"2013","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejmech.2014.05.076_bib33","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1073\/pnas.0909310107","article-title":"Neuroprotection by selective allosteric potentiators of the EP2 prostaglandin receptor","volume":"107","author":"Jiang","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352341400508X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352341400508X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,11]],"date-time":"2019-08-11T02:30:25Z","timestamp":1565490625000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S022352341400508X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":33,"alternative-id":["S022352341400508X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2014.05.076","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of second generation EP2 antagonists with high selectivity","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2014.05.076","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}